JPWO2021241523A1 - - Google Patents

Info

Publication number
JPWO2021241523A1
JPWO2021241523A1 JP2022526545A JP2022526545A JPWO2021241523A1 JP WO2021241523 A1 JPWO2021241523 A1 JP WO2021241523A1 JP 2022526545 A JP2022526545 A JP 2022526545A JP 2022526545 A JP2022526545 A JP 2022526545A JP WO2021241523 A1 JPWO2021241523 A1 JP WO2021241523A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526545A
Other languages
Japanese (ja)
Other versions
JP7754455B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021241523A1 publication Critical patent/JPWO2021241523A1/ja
Application granted granted Critical
Publication of JP7754455B2 publication Critical patent/JP7754455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022526545A 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物 Active JP7754455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
JP2020090526 2020-05-25
PCT/JP2021/019676 WO2021241523A1 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2021241523A1 true JPWO2021241523A1 (https=) 2021-12-02
JP7754455B2 JP7754455B2 (ja) 2025-10-15

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526545A Active JP7754455B2 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Country Status (7)

Country Link
US (1) US20230183347A1 (https=)
EP (1) EP4159235A4 (https=)
JP (1) JP7754455B2 (https=)
KR (1) KR20230015348A (https=)
CN (1) CN115697405A (https=)
TW (1) TWI890796B (https=)
WO (1) WO2021241523A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022091A1 (ja) * 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
CN106924718A (zh) * 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
CN107149680A (zh) * 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
WO2019168745A1 (en) * 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof
JP2019531284A (ja) * 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022091A1 (ja) * 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
JP2019531284A (ja) * 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
CN106924718A (zh) * 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
CN107149680A (zh) * 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
WO2019168745A1 (en) * 2018-03-02 2019-09-06 Eli Lilly And Company Pd-1 agonist antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUREUS, vol. vol.9, issue 4, JPN6025014164, 2017, pages 1177 - 1, ISSN: 0005569211 *
GUT, vol. vol.64, issue 2, JPN6025014163, 2015, pages 260 - 271, ISSN: 0005569210 *
LEWKOWICH, IP., ET AL.: "PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production", MUCOSAL IMMUNOL., vol. 6, no. 4, JPN6021027453, 2013, pages 728 - 739, ISSN: 0005569209 *
MCALEES, J.W., ET AL.: "Differential control of CD4+ T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asth", EUR. J. IMMUNOL., vol. vol.45, issue 4, JPN6021027455, 2015, pages 1019 - 1029, ISSN: 0005569208 *
OFLAZOGLU, E., ET AL.: "Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asth", EUR. J. IMMUNOL., vol. vol.34, issue 12, JPN6021027457, 2004, pages 3326 - 3336, ISSN: 0005569207 *

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
CN115697405A (zh) 2023-02-03
EP4159235A1 (en) 2023-04-05
TWI890796B (zh) 2025-07-21
KR20230015348A (ko) 2023-01-31
EP4159235A4 (en) 2024-07-10
JP7754455B2 (ja) 2025-10-15
WO2021241523A1 (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2021241523A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR112021013417A2 (https=)

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250924

R150 Certificate of patent or registration of utility model

Ref document number: 7754455

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150